Standard treatment in advanced ovarian cancer in 2005: the state of the art
- PMID: 16343233
- DOI: 10.1111/j.1525-1438.2005.00444.x
Standard treatment in advanced ovarian cancer in 2005: the state of the art
Abstract
What are standards? The oncology community expends considerable effort to review the results from definitive treatment studies and define recommendations for future studies, as well as standards of care for the community and patients who are not participating in clinical trials. This is a thoughtful and well-intentioned process but subject to considerable bias due to limitations in the data and/or their interpretation. While ovarian cancer is highly responsive to platinum-based therapy after initial cytoreductive surgery, there is a substantial risk of recurrence, which is accompanied by the emergence of drug-resistant disease. Better treatments with improved long-term outcomes are needed. From this perspective, standards can help to provide a baseline for assessing gaps in our current knowledge and defining priorities for future clinical trials. While not an exhaustive review, this study will focus on key clinical concepts that are guiding ovarian cancer research and treatment.
Similar articles
-
Evolution of the Gynecologic Oncology Group protocols in the treatment of epithelial ovarian cancer.Clin Obstet Gynecol. 2012 Mar;55(1):131-55. doi: 10.1097/GRF.0b013e318248050d. Clin Obstet Gynecol. 2012. PMID: 22343234 Review.
-
Advances in the management of epithelial ovarian cancer.J Reprod Med. 2005 Jun;50(6):426-38. J Reprod Med. 2005. PMID: 16050567 Review.
-
Survival outcomes after extensive cytoreductive surgery and selective neoadjuvant chemotherapy according to institutional criteria in bulky stage IIIC and IV epithelial ovarian cancer.J Gynecol Oncol. 2017 Jul;28(4):e48. doi: 10.3802/jgo.2017.28.e48. J Gynecol Oncol. 2017. PMID: 28541636 Free PMC article.
-
Hyperthermic intraperitoneal chemotherapy in ovarian cancer: first report of the HYPER-O registry.Int J Gynecol Cancer. 2010 Jan;20(1):61-9. doi: 10.1111/IGC.0b013e3181c50cde. Int J Gynecol Cancer. 2010. PMID: 20130504
-
Chemotherapy for ovarian cancer: an evidence-based approach.Minerva Ginecol. 2004 Dec;56(6):539-45. Minerva Ginecol. 2004. PMID: 15729206 Review.
Cited by
-
Potential target antigens for a universal vaccine in epithelial ovarian cancer.Clin Dev Immunol. 2010;2010:891505. doi: 10.1155/2010/891505. Epub 2010 Sep 15. Clin Dev Immunol. 2010. PMID: 20885926 Free PMC article.
-
CAR-T cell therapy in ovarian cancer: from the bench to the bedside.Oncotarget. 2017 Aug 4;8(38):64607-64621. doi: 10.18632/oncotarget.19929. eCollection 2017 Sep 8. Oncotarget. 2017. PMID: 28969098 Free PMC article. Review.
-
Relationship between ERCC1 polymorphisms, disease progression, and survival in the Gynecologic Oncology Group Phase III Trial of intraperitoneal versus intravenous cisplatin and paclitaxel for stage III epithelial ovarian cancer.J Clin Oncol. 2008 Jul 20;26(21):3598-606. doi: 10.1200/JCO.2008.16.1323. J Clin Oncol. 2008. PMID: 18640939 Free PMC article. Clinical Trial.
-
Meiotic protein SYCP2 confers resistance to DNA-damaging agents through R-loop-mediated DNA repair.Nat Commun. 2024 Feb 21;15(1):1568. doi: 10.1038/s41467-024-45693-2. Nat Commun. 2024. PMID: 38383600 Free PMC article.
-
A phase I clinical trial of adoptive T cell therapy using IL-12 secreting MUC-16(ecto) directed chimeric antigen receptors for recurrent ovarian cancer.J Transl Med. 2015 Mar 28;13:102. doi: 10.1186/s12967-015-0460-x. J Transl Med. 2015. PMID: 25890361 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical